Lenacapavir - CAS 2189684-44-2

Lenacapavir (GS-6207) is the first HIV-1 capsid inhibitor approved by the U.S. Food and Drug Administration, the European Medicines Agency, and Health Canada for the treatment of MDR HIV-1 infection.[3]

HIV Protease

Microbiology/Virology, Proteases/Proteasome

2189638

>99.99%

C39H32ClF10N7O5S2

968.28

[H][C@]12C[C@@]1([H])C(F)(F)c1c2c(nn1CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)c1nc(ccc1-c1ccc(Cl)c2c(NS(C)(=O)=O)nn(CC(F)(F)F)c12)C#CC(C)(C)S(C)(=O)=O)C(F)(F)F

-20°C

Ice Packs

Small Compound